STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions. It also provides capital equipment install, maintain, upgrade, repair, and troubleshoot services. This segment provides its products and services to acute care hospitals, ambulatory surgery centers, and GI clinics. The Healthcare Specialty Services segment provides solutions and managed services, including instrument and endoscope repair and maintenance solutions; and custom process improvement consulting and outsourced sterile processing services to acute care hospitals and other healthcare settings. The Life Sciences segment offers formulated cleaning chemistries, barrier products, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. The Applied Sterilization Technologies segment provides contract sterilization services using gamma, electron beam, and X-ray technologies, as well as ethylene oxide and hydrogen peroxide; and laboratory testing services. It operates a network of approximately 50 facilities. The company was founded in 1985 and is based in Derby, the United Kingdom.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone44-13-3238-7100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.62 billion
Profitability
Miscellaneous
Employees12,000
OptionableOptionable
Steris (NYSE:STE) Frequently Asked Questions
What is Steris' stock symbol?
Steris trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."
How often does Steris pay dividends? What is the dividend yield for Steris?
Steris declared a quarterly dividend on Friday, October 26th. Investors of record on Wednesday, November 28th will be given a dividend of $0.34 per share on Friday, December 21st. This represents a $1.36 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date is Tuesday, November 27th. View Steris' Dividend History.
How were Steris' earnings last quarter?
Steris PLC (NYSE:STE) released its earnings results on Tuesday, November, 6th. The medical equipment provider reported $1.10 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.02. The medical equipment provider had revenue of $679 million for the quarter, compared to analyst estimates of $659.14 million. Steris had a return on equity of 12.15% and a net margin of 11.72%. Steris's revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.94 EPS. View Steris' Earnings History.
When is Steris' next earnings date?
What guidance has Steris issued on next quarter's earnings?
Steris updated its FY19 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $4.74-4.84 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.70. Steris also updated its FY 2019 guidance to $4.74-4.84 EPS.
What price target have analysts set for STE?
5 equities research analysts have issued 12 month price targets for Steris' stock. Their forecasts range from $102.00 to $157.00. On average, they anticipate Steris' stock price to reach $128.20 in the next year. This suggests a possible upside of 13.8% from the stock's current price. View Analyst Price Targets for Steris.
What is the consensus analysts' recommendation for Steris?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steris in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Steris.
What are Wall Street analysts saying about Steris stock?
Here are some recent quotes from research analysts about Steris stock:
- 1. According to Zacks Investment Research, "STERIS exited second-quarter fiscal 2019 on a promising note with earnings and revenues both exceeding the respective Zacks Consensus Estimate. We are impressed with the company’s persistently strong organic growth performance across major segments. The company is currently demonstrating strong top line growth on favorable underlying market trends along with new product and service offerings. Further, growth in free cash flow reserve is indicative of the company’s strong cash balance. The company raising its overall guidance for fiscal 2019 is also indicative of brighter prospects. STERIS has also made certain acquisitions, divestments and organizational changes, which are expected to better align with its operations. Over the past three months, STERIS has been outperforming its industry." (11/16/2018)
- 2. KeyCorp analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $21.3/share, as a 25x multiple of taxed and diluted $11.7 discounted back to FY18 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $21.3/ share (discounted cash flow analysis using a 20% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/9/2018)
Has Steris been receiving favorable news coverage?
Media headlines about STE stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Steris earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are some of Steris' key competitors?
Some companies that are related to Steris include Edwards Lifesciences (EW), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Invacare (IVC) and Lakeland Industries (LAKE).
Who are Steris' key executives?
Steris' management team includes the folowing people:
- Mr. Walter M. Rosebrough Jr., CEO, Pres & Director (Age 64)
- Mr. Michael J. Tokich, Sr. VP & CFO (Age 49)
- Mr. Daniel A. Carestio, Chief Operating Officer (Age 45)
- Mr. John Adam Zangerle, VP, Gen. Counsel & Sec. (Age 51)
- Dr. Adrian Vincent Coward, Sr. VP of Healthcare Specialty Services (Age 48)
Who are Steris' major shareholders?
Steris' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Villere ST Denis J & Co. LLC (0.70%), Bank of Montreal Can (0.35%), BTIM Corp. (0.15%), Retirement Systems of Alabama (0.13%), Kavar Capital Partners LLC (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Steris stock include Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Richard Martin Steeves, Sudhir K Pahwa, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Institutional Ownership Trends for Steris.
Which institutional investors are selling Steris stock?
STE stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Bank of Montreal Can, Meeder Asset Management Inc., Nisa Investment Advisors LLC, Louisiana State Employees Retirement System, First Citizens Bank & Trust Co., Oakbrook Investments LLC and Kavar Capital Partners LLC. Company insiders that have sold Steris company stock in the last year include Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Richard Martin Steeves, Sudhir K Pahwa, Walter M Rosebrough Jr and Walter M Rosebrough, Jr. View Insider Buying and Selling for Steris.
Which institutional investors are buying Steris stock?
STE stock was bought by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, BTIM Corp., Gateway Investment Advisers LLC, Fulton Bank N.A., Cerebellum GP LLC, Virtu Financial LLC, First Hawaiian Bank and Fox Run Management L.L.C.. View Insider Buying and Selling for Steris.
How do I buy shares of Steris?
Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Steris' stock price today?
One share of STE stock can currently be purchased for approximately $112.70.
How big of a company is Steris?
Steris has a market capitalization of $9.52 billion and generates $2.62 billion in revenue each year. The medical equipment provider earns $290.91 million in net income (profit) each year or $4.15 on an earnings per share basis. Steris employs 12,000 workers across the globe.
What is Steris' official website?
How can I contact Steris?
Steris' mailing address is Rutherford House Stephensons Way Chaddesden, Derby X0, DE21 6LY. The medical equipment provider can be reached via phone at 44-13-3238-7100 or via email at [email protected]
MarketBeat Community Rating for Steris (NYSE STE)
MarketBeat's community ratings are surveys of what our community members think about Steris and other stocks. Vote "Outperform" if you believe STE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STE will underperform the S&P 500 over the long term. You may vote once every thirty days.
